Forsteo ® (teriparatide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Forsteo Summary of Product Characteristics (SmPC)

Forsteo® (teriparatide): Use With COVID-19 Vaccines

The use of vaccines against SARS-CoV-2 in patients treated with teriparatide [rDNA origin] injection has not been studied.

Administration of COVID-19 Vaccines to Patients Receiving Teriparatide

Severe acute respiratory syndrome coronavirus 2 is an emerging virus that has caused the recent COVID-19 pandemic.1 Recently, vaccines have been developed against SARS-CoV-2 and additional vaccines are expected to be available in the coming months.2

SARS-CoV-2 Vaccination With Teriparatide

The use of a SARS-CoV-2 vaccine in patients treated with teriparatide has not been studied by Lilly.

Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with teriparatide should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient as well as the risks and benefits of vaccination. Consultation with an infectious disease expert may be helpful in high-risk or emergency situations such as the current COVID-19 pandemic.

Vaccination Against COVID-19 Treatment Guidance in Patients With Osteoporosis

Recommendations for the management of patients with osteoporosis in relation to COVID-19 vaccination have been published by the International Osteoporosis Foundation.3

For the most current information please refer to Joint Guidance on COVID-19 Vaccination and Osteoporosis Management.3

 

Further information on COVID-19 vaccines and osteoporosis is available at the web page of the Royal Osteoporosis Society at Coronavirus and osteoporosis.4

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to

References

1. Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y

2. Su Z, Wen J, McDonnell D, et al. Vaccines are not yet a silver bullet: the imperative of continued communication about the importance of COVID-19 safety measures. Brain Behav Immun Health. 2021;12:100204. https://doi.org/10.1016/j.bbih.2021.100204

3. Joint Guidance on COVID-19 Vaccination and Osteoporosis Management. The International Osteoporosis Foundation. March 9, 2021. Accessed March 26, 2021. https://www.osteoporosis.foundation/news/joint-guidance-covid-19-vaccination-and-osteoporosis-management-20210309-1500

4. Coronavirus and osteoporosis. Royal Osteoporosis Society. December 11, 2020. Accessed May 3, 2021. https://theros.org.uk/information-and-support/osteoporosis/coronavirus/

5. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 26, 2021. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19

6. COVID-19. European Centre for Disease Prevention and Control. Accessed March 26, 2021. https://www.ecdc.europa.eu/en/novel-coronavirus-china

Glossary

COVID-19 = coronavirus disease 2019

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

EU WHO = World Health Organization (European regional office)

ECDC = European Centre for Disease Prevention and Control

Date of Last Review: January 11, 2021


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request